General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Drugmaker Endo receives US court approval for bankruptcy restructuring | reuters.com • |
Drugmaker Endo reaches $465 mln bankruptcy settlement with US government | reuters.com • |
How to Invest in Meme Penny Stocks in 2022 | pennystocks.com • |
Endo (ENDP) Files for Bankruptcy Amid Litigations, Huge Debt | zacks.com • |
Percocet maker Endo International files for bankruptcy | foxbusiness.com • |
Best Penny Stocks to Buy Now? 3 For Your August List | pennystocks.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2022-08-09 | 2022-06 | -0.16 | N/A | N/A | N/A |
2022-05-05 | 2022-03 | 0.44 | N/A | N/A | N/A |
2022-02-28 | 2021-12 | 0.7 | N/A | N/A | N/A |
2021-11-04 | 2021-09 | 0.46 | N/A | N/A | N/A |
2021-08-05 | 2021-06 | 0.42 | N/A | N/A | N/A |
2021-05-06 | 2021-03 | 0.48 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2022-05-08 | Barclays | Upgrade | Underweight | |
2022-05-08 | BMO Capital | Upgrade | Market Perform | |
2022-03-08 | Citigroup | Upgrade | Buy | |
2022-03-01 | Barclays | Downgrade | Equal-Weight | Underweight |
2022-03-01 | Piper Sandler | Upgrade | Neutral | |
2021-12-15 | Barclays | Upgrade | Equal-Weight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2021-06-10 | BARBERIO MARK G | Director | 38.19K | Stock Award(Grant) |
2022-03-29 | BARRY PATRICK A | Officer | 169.71K | Conversion of Exercise of derivative security |
2022-03-29 | BRADLEY MARK T | Chief Financial Officer | 101.48K | Conversion of Exercise of derivative security |
2021-06-10 | CHAO JENNIFER M | Director | 24.92K | Stock Award(Grant) |
2022-03-29 | COLEMAN BLAISE | Chief Executive Officer | 422.07K | Conversion of Exercise of derivative security |
2021-06-10 | COOKE SHANE M | Director | 100.03K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-06-29 | Vanguard Group, Inc. (The) | 25.39M | 11.82M | 10.80% |
2022-06-29 | Blackrock Inc. | 18.63M | 8.68M | 7.92% |
2022-06-29 | Renaissance Technologies, LLC | 12.52M | 5.83M | 5.32% |
2022-06-29 | Paulson & Company, Inc. | 7.79M | 3.63M | 3.31% |
2022-06-29 | AQR Capital Management, LLC | 6.39M | 2.98M | 2.72% |
2022-06-29 | Acadian Asset Management. LLC | 6.01M | 2.80M | 2.56% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-03-30 | Vanguard Tax Managed Fund-Small Cap Fund | 2.17M | 5.01M | 0.92% |
2022-03-30 | Vanguard Strategic Equity Fund | 1.85M | 4.27M | 0.79% |
2022-05-30 | Fidelity Small Cap Index Fund | 1.68M | 889.17K | 0.72% |
2022-05-30 | Fidelity Extended Market Index Fund | 1.17M | 619.12K | 0.50% |
2022-03-30 | JP Morgan Small Cap Value Fund | 1.11M | 2.57M | 0.47% |
2022-04-29 | DFA U.S. Small Cap Series | 988.87K | 1.98M | 0.42% |
$ENDP Pump up the volume!!!
It has also achieved an agreement in principle with Attorneys General from North Carolina, Pennsylvania, Tennessee and Texas, as well as certain defendants, for a global settlement framework. Under this agreement, the company would donate $23B (wholesale value) of Suboxone over the next 10 years plus up to $250M in cash over the same time frame.
$MNK $ENDP $TEVA Thank you folks for all your comments. You are boldly contributing to my trading education and success. And M5IVE on other subjects as well... Thank you for you unleashed comments and humour.
I come from a field which I initially thought had nothing to do with trading and finally discovered has everything to do with it, which is psychology. Apart from knowledge and information, successful trading is about emotion and stress management, and being aware of your decision process. But as experienced traders you must have realized that a long time ago.
Those discussion groups also brought back a fundamental conclusion: alone, we are nothing. Thank you all.
Law360 Health HEALTH
Wednesday, October 16, 2019 Follow Health Law360
BREAKING: J&J, Teva, Distributors Float Deals Worth $50B To End Opioid Cases
Major drug manufacturers and distributors are proposing deals that could be worth a combined $50 billion to resolve large portions of nationwide litigation over pharmaceutical industry liability for the opioid crisis, according to a source with direct knowledge of the offers.